iShares MSCI Hong Kong ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? iShares MSCI Hong Kong ETF trades at $22.09 (market cap $1.16B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.71 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| EWH | SLS | |
|---|---|---|
Market Cap | $1.16B | $2.27B |
Volume | 3,176,523 | 4,179,659 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $15.46 |
52-Week Low | $20.66 | $1.39 |
Typical Hold Time | 61 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.06 with a 2.22% daily gain but maintains a bearish technical outlook. The ETF tracks Hong Kong equities, which face headwinds from Federal Reserve policy and US-Iran tensions, as the Hang Seng Index has declined over 11% from yearly highs. Moving averages signal strong bearish momentum while oscillators show neutral conditions, with key support at $21.
The outlook remains cautious given Hong Kong's sensitivity to US-China relations and Fed policy. Near-term performance hinges on geopolitical developments and Chinese economic data. Risks include continued institutional selling and Hang Seng volatility, but oversold conditions may attract contrarian buyers if tensions ease.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →